Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from InspireMD ( (NSPR) ).
On June 3, 2025, InspireMD, Inc. conducted its annual meeting of stockholders, where 66.84% of the shares were represented, constituting a quorum. During the meeting, stockholders re-elected Michael Berman and Scott R. Ward as Class 2 directors for a three-year term and ratified Kesselman & Kesselman as the independent auditors for the 2025 fiscal year.
The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.
Spark’s Take on NSPR Stock
According to Spark, TipRanks’ AI Analyst, NSPR is a Neutral.
InspireMD’s score is driven by financial challenges and valuation concerns, despite some growth potential highlighted in the earnings call. The company’s profitability issues and negative cash flow are significant risks, while technical analysis and growth prospects provide some balance.
To see Spark’s full report on NSPR stock, click here.
More about InspireMD
InspireMD, Inc. operates in the medical device industry, focusing on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary artery diseases.
Average Trading Volume: 51,864
Technical Sentiment Signal: Sell
Current Market Cap: $77.81M
For detailed information about NSPR stock, go to TipRanks’ Stock Analysis page.